We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current 0KCC market cap is 6.05B. The company's latest EPS is USD -0.6190 and P/E is -4.20.
| Year End December 30 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 5.23M | 7.73M | 31.98M |
| Operating Income | -15.2M | -22.52M | -31.26M | -74.48M | -18M |
| Net Income | -15.75M | -22.43M | -29.93M | -64.1M | -73.42M |
| Year End December 30 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 9.52M | 39.86M | 55.42M | 159.56M | 100.09M |
| Total Liabilities | 6.1M | 9.02M | 21.94M | 94.35M | 60.5M |
| Total Equity | 3.42M | 30.84M | 33.48M | 65.22M | 34.29M |
| Year End December 30 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -11.65M | -19.72M | -25.98M | -35.94M | -45.57M |
| Investing | -31k | -12.42M | -11.75M | -13.96M | -4.34M |
| Financing | 12.11M | 47.87M | 22.8M | 78.75M | 35.81M |
| Market Cap | 6.05B |
| Price to Earnings Ratio | -4.20 |
| Price to Sales Ratio | 9.64 |
| Price to Cash Ratio | 15.43 |
| Price to Book Ratio | 7.79 |
| Dividend Yield | - |
| Shares Outstanding | 118.62M |
| Average Volume (1 week) | 904 |
| Average Volume (1 Month) | 682 |
| 52 Week Change | 0.00% |
| 52 Week High | 51.00 |
| 52 Week Low | 51.00 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Oncocyte Corp |
| Address |
15 cushing irvine, california 92618 |
| Website | https://www.oncocyte.com |
| Industry | in vitro,in vivo diagnostics (2835) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
